PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
|
|
|
- Blanche Gilbert
- 5 years ago
- Views:
Transcription
1 PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Zoledronic acid PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP: MALE FEMALE SPECIAL REQUIREMENTS: (e.g. other language/other communication method) RESPONSIBLE HEALTH PROFESSIONAL: Name: NAME OF PROPOSED COURSE OF TREATMENT (include brief explanation if medical term not clear) Zoledronic acid for the treatment of cancer. Given intravenously at a minimum interval of 3 weeks. Treatment is continued until disease progression or unacceptable toxicity. OR Given intravenously every 6 months, for 3 to 5 years. WHERE THE TREATMENT WILL BE GIVEN: outpatient day unit/case inpatient other: STATEMENT OF HEALTH PROFESSIONAL (to be filled in by health professional with appropriate knowledge of proposed procedure, as specified in the hospital/trust s consent policy) I have explained the procedure/treatment to the patient. In particular, I have explained: all relevant boxes THE INTENDED BENEFITS ADJUVANT therapy given after surgery/radiotherapy and with/after chemotherapy to reduce the risk of the cancer coming back. To reduce and prevent symptoms and events related to the spread of the cancer to the bones. Page 1 of 5
2 STATEMENT OF HEALTH PROFESSIONAL (continued) SIGNIFICANT, UNAVOIDABLE OR FREQUENTLY OCCURRING RISKS COMMON SIDE EFFECTS: More than 10 in every 100 (>10%) people have one or more of the side effects listed: Low levels of phosphate in the blood. OCCASIONAL SIDE EFFECTS: Between 1 and 10 in every 100 (1-10%) people have one or more of these effects: Bone, joint and muscle pain, flu-like symptoms, high temperature (fever), headache, feeling sick (nausea) and being sick (nausea), loss of appetite, low levels of calcium in the blood, red or sore eyes, anaemia (low number of red blood cells), and changes in the way the kidneys work. OTHER RISKS: Uncommon and rare effects affecting fewer than 1 in 100 (<1%) people include: allergic reactions, injection site reactions, bruising and bleeding due to low numbers of platelets, anxiety, sleep disturbances, blood pressure changes, and changes in heart rate. There is an uncommon but serious risk of developing jaw problems (osteonecrosis) in people who are treated with zoledronic acid. This is when healthy bone tissue in the jaw becomes damaged and dies. Gum disease, problems with your dentures, and some dental treatments (such as having a tooth removed) can increase the risk of this. A dental examination is recommended before starting treatment with zoledronic acid. There is a rare but serious risk of a fracture/break in the thigh bone in people who are treated with zoledronic acid. It is important to tell your doctor or nurse if you have any pain in the thigh, hip or groin area. It is unknown if zoledronic acid damages the development of a baby in the womb. It is important not to become pregnant while you are having treatment. It is important for women of child-bearing potential to use effective contraception during treatment. You can talk to your doctor or nurse about this. Page 2 of 5
3 STATEMENT OF HEALTH PROFESSIONAL (continued) ANY OTHER RISKS: I have discussed what the treatment is likely to involve (including inpatient / outpatient treatment, timing of the treatment, blood and any additional tests, follow-up appointments etc) and location. I have discussed the intended benefits and risks of any available alternative treatments (including no treatment) and any particular concerns of this patient. THE FOLLOWING LEAFLET HAS BEEN PROVIDED: Information leaflet for zoledronic acid. 24 hour chemotherapy service contact details Other, please state: STATEMENT OF INTERPRETER (where appropriate) INTERPRETER BOOKING REFERENCE (if applicable): I have interpreted the information above to the patient to the best of my ability and in a way in which I believe s/he can understand. Page 3 of 5
4 STATEMENT OF PATIENT Please read this form carefully. If your treatment has been planned in advance, you should already have your own copy of the form which describes the benefits and risks of the proposed treatment. If not, you will be offered a copy now. If you have any further questions, do ask we are here to help you. You have the right to change your mind at any time, including after you have signed this form. I agree to the procedure and course of treatment described on this form. I understand that you cannot give me a guarantee that a particular person will perform the procedure. The person will, however, have appropriate training and experience. I understand that any procedure in addition to those described on this form will only be carried out if it is necessary to save my life or to prevent serious harm to my health. I have been told about additional procedures which may become necessary during my treatment. I have listed below any procedures which I do not wish to be carried out without further discussion: Patient s signature: A witness should sign below if the patient is unable to sign but has indicated his or her consent. Young people/children may also like a parent to sign here (see notes). Parent s/witness signature: COPY ACCEPTED BY PATIENT: YES / NO (please circle) CONFIRMATION OF CONSENT (health professional to complete when the patient attends for treatment, if the patient has signed the form in advance) On behalf of the team treating the patient, I have confirmed with the patient that s/he has no further questions and wishes the procedure to go ahead. IMPORTANT NOTES: (tick if applicable) See also advance decision to refuse treatment Patient has withdrawn consent (ask patient to sign /date here) FURTHER INFORMATION FOR PATIENTS CONTACT DETAILS (if patient wishes to discuss options later): Contact your hospital team if you have any questions about cancer and treatment. Cancer Research UK can also help answer your questions about cancer and treatment. If you want to talk in confidence, call our information nurses on freephone , Monday to Friday, 9am to 5pm. Alternatively visit for more information. These forms have been produced by Guy s and St. Thomas NHS Foundation Trust as part of a national project to support clinicians in ensuring all patients are fully informed when consenting to SACT. The project is supported by Cancer Research UK. This does not mean you are taking part in a clinical trial. Page 4 of 5
5 GUIDANCE FOR HEALTH PROFESSIONALS (to be read in conjunction with the hospital s consent policy) WHAT A CONSENT FORM IS FOR This form documents the patient s agreement to go ahead with the investigation or treatment you have proposed. It is not a legal waiver if patients, for example, do not receive enough information on which to base their decision, then the consent may not be valid, even though the form has been signed. Patients are also entitled to change their mind after signing the form, if they retain capacity to do so. The form should act as an aide-memoir to health professionals and patients, by providing a checklist of the kind of information patients should be offered, and by enabling the patient to have a written record of the main points discussed. In no way, however, should the written information provided for the patient be regarded as a substitute for face-to-face discussions with the patient. THE LAW ON CONSENT See the Department of Health s Reference guide to consent for examination or treatment 2nd Edition for a comprehensive summary of the law on consent (also available at WHO CAN GIVE CONSENT Everyone aged 16 or over is presumed to have the capacity to give consent for themselves, unless the opposite is demonstrated. If a child under the age of 16 has sufficient understanding and intelligence to enable him or her to understand fully what is proposed, then he or she will have capacity to give consent for himself or herself. Young people aged 16 and 17, and younger children with capacity, may therefore sign this form for themselves, but may like a parent to countersign as well. If the child is not able to give consent for himself or herself, someone with parental responsibility may do so on their behalf and a separate form is available for this purpose. Even where a child is able to give consent for himself or herself, you should always involve those with parental responsibility in the child s care, unless the child specifically asks you not to do so. If a patient has the capacity to give consent but is physically unable to sign a form, you should complete this form as usual, and ask an independent witness to confirm that the patient has given consent orally or non-verbally. WHEN NOT TO USE THIS FORM If the patient is 18 or over and lacks the capacity to give consent, you should use an alternative form (form for adults who lack the capacity to consent to investigation or treatment) instead of this form. A patient lacks capacity if they have an impairment of the mind or brain or disturbance affecting the way their mind or brain works and they cannot: understand information about the decision to be made retain that information in their mind use or weigh this information as a part of their decision making process, or communicate their decision (by talking, using sign language or any other means) You should always take all reasonable steps (for example involving more specialist colleagues) to support a patient in making their own decision, before concluding that they are unable to do so. Relatives cannot be asked to sign a form on behalf of an adult who lacks capacity to consent for themselves, unless they have been given the authority to do so under a Lasting Power of Attorney or as a court deputy. INFORMATION Information about what the treatment will involve, its benefits and risks (including side-effects and complications) and the alternatives to the particular procedure proposed, is crucial for patients when making up their minds. The courts have stated that patients should be told about significant risks which would affect the judgement of a reasonable patient. Significant has not been legally defined, but the GMC requires doctors to tell patients about significant, unavoidable or frequently occurring risks. In addition if patients make clear they have particular concerns about certain kinds of risk, you should make sure they are informed about these risks, even if they are very small or rare. You should always answer questions honestly. Sometimes, patients may make it clear that they do not want to have any information about the options, but want you to decide on their behalf. In such circumstances, you should do your best to ensure that the patient receives at least very basic information about what is proposed. Where information is refused, you should document this on the consent form or in the patient s notes. REFERENCES 1. Summary of Product Characteristics (SPCs) for individual drugs: 2. Cancer Research UK: about-cancer/cancers-in-general/treatment/cancer-drugs/ 3. Macmillan Cancer Support, Cancer Information: macmillan.org.uk/cancerinformation/cancertreatment/ Treatmenttypes/Chemotherapy/Chemotherapy.aspx 4. Guy s and St. Thomas NHS Foundation Trust, Chemotherapy consent forms. Page 5 of 5
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Dabrafenib-Trametinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Atezolizumab PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Everolimus PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Carboplatin-Etoposide PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Gemcitabine- Carboplatin PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Pembrolizumab PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Niraparib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Bevacizumab + Chemotherapy PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Irinotecan- Capecitabine (CAPIRI) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier)
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Nintedanib-Docetaxel PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: BEP (5 day) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cisplatin- Capecitabine- Trastuzumab PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier)
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Docetaxel-EC PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Axitinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: FEC-P PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP: MALE
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Oxaliplatin- Fluorouracil (FOLFOX) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier)
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Sunitinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Ponatinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Pazopanib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Docetaxel-Oxaliplatin- Fluorouracil (FLOT) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cabozantinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ZOLEDRONIC ACID. Patient s first names.
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ZOLEDRONIC ACID Patient s surname/family name Patient s first names Date of birth NHS number (or other identifier)
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CISPLATIN + ETOPOSIDE ORAL/INTRAVENOUS
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CISPLATIN + ETOPOSIDE ORAL/INTRAVENOUS Patient s surname/family name Patient s first names Date of birth Hospital
Patient identifier/label: Page 1 of 7 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM EC-T: EPIRUBICIN / CYCLOPHOSPHAMIDE - DOCETAXEL
Patient identifier/label: Page 1 of 7 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM EC-T: EPIRUBICIN / CYCLOPHOSPHAMIDE - DOCETAXEL Patient s surname/family name Patient s first names Date of birth
Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM BEVACIZUMAB. Patient s first names. Date of birth.
Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM BEVACIZUMAB Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number (or other
PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM FERRERI / IELSG PROTOCOL. Patient s first names. Date of birth
Page 1 of 6 FORM FERRERI / IELSG PROTOCOL Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital NHS
Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CABOZANTINIB. Patient s first names.
Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CABOZANTINIB Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number (or other
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ABVD. Patient s first names.
Patient identifier/label: Page 1 of 6 Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital NHS number
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CHOP 21 +/- RITUXIMAB. Patient s first names.
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CHOP 21 +/- RITUXIMAB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CYTARABINE (HIGH DOSE)
Patient identifier/label: Page 1 of 6 CYTARABINE Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital
Patient's surname/family name. Patient's first names. Date of birth. Responsible health professional. Job title. NHS number (or other identifier)
Page 1 of7 Patient's surname/family name Department of Health THE ROYAL MARSDEN NHS FOUNDATION TRUST Robotic-assisted Laparoscopic Prostatectomy (RALP) Patient Agreement to Investigation or Treatment Patient's
Patient agreement to investigation or treatment. Spinal Injections. Patient details (or pre-printed label) Patient s surname/family name...
CONSENT FORM 1(VII) Patient agreement to investigation or treatment Spinal Injections Patient details (or pre-printed label) Patient s surname/family name..... Patient s first names.. Date of birth. Responsible
Patient agreement to investigation or treatment. Emergency Spinal Discectomy/Decompression. Patient details (or pre-printed label)
CONSENT FORM 1 (VI) Patient agreement to investigation or treatment Emergency Spinal Discectomy/Decompression Patient details (or pre-printed label) Patient s surname/family name..... Patient s first names..
Laparoscopic radical nephrectomy
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is a laparoscopic radical nephrectomy? This is a procedure which involves removal
Percutaneous nephrolithotomy (PCNL)
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What does this procedure involve? The breakdown and removal of kidney stones using
Fitting of an Intrauterine Device (IUD)
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is an IUD? An IUD is a small T-shaped plastic and copper device that is put into
1231 Zoledronic acid in early breast cancer Page 1 of 5
Zoledronic acid in early breast cancer Zoledronic acid in early breast cancer Zoledronic acid is a bisphosphonate. This is treatment which works by slowing down the rate of bone change. In the bone there
Direct Current Cardioversion (DCCV)
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is a This is a procedure carried out under a brief anaesthetic, which uses a
Diagnostic and therapeutic pleural aspiration
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient Diagnostic and therapeutic pleural aspiration affix patient label Who is this leaflet for? This leaflet
Deciding whether a person has the capacity to make a decision the Mental Capacity Act 2005
Deciding whether a person has the capacity to make a decision the Mental Capacity Act 2005 April 2015 Deciding whether a person has the capacity to make a decision the Mental Capacity Act 2005 The RMBI,
Transperineal ultrasound-guided biopsy of the prostate gland
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient biopsy of the prostate gland affix patient label What is a transperineal (TP) ultrasound-guided prostate
Planning for a time when you cannot make decisions for yourself
Planning for a time when you cannot make decisions for yourself An information leaflet for members of the public Version: October 2013 Introduction The Mental Capacity Act 2005 allows you to plan ahead
Mastoidectomy or combined approach tympanoplasty
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is a cholesteatoma? This is a cyst of skin cells behind your eardrum. As it gets
Canalplasty / excision of exostoses
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is a canalplasty? A canalplasty is an operation to remove exostoses, which are
Advance Statements. What is an Advance Statement? Information Line: Website: compassionindying.org.uk
Information Line: 0800 999 2434 Website: compassionindying.org.uk This factsheet explains what an Advance Statement is and how to make one. It is for people living in England and Wales. If you live in
Percutaneous coronary intervention (angioplasty) +/- rotablation
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label Why do I need this procedure? If you are coming into hospital for a cardiac procedure
Fractured neck of femur
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is a fractured neck of femur? A healthy hip joint is vital to normal walking
PACKAGE LEAFLET: INFORMATION FOR THE USER. Zoledronic Acid IBIGEN 4 mg powder and solvent for solution for infusion Zoledronic acid
PACKAGE LEAFLET: INFORMATION FOR THE USER Zoledronic Acid IBIGEN 4 mg powder and solvent for solution for infusion Zoledronic acid Read all of this leaflet carefully before you are given Zoledronic Acid
Assessment of Mental Capacity and Best Interest Decisions
Standard Operating Procedure 1 (SOP 1) Assessment of Mental Capacity and Best Interest Decisions Why we have a procedure? This Standard Operating Procedure (SOP) is required to set out how a person s capacity
West Suffolk Hospital
For staff use only: Patient Details: First names: Hospital no: (Use hospital identification label) West Suffolk Hospital Patient information leaflet Carpal Tunnel Syndrome 2-3 Patient agreement to investigation
CONSENT FORM UROLOGICAL SURGERY
CONSENT FORM for UROLOGICAL SURGERY (Designed in compliance with consent form 1) PATIENT AGREEMENT TO INVESTIGATION OR TREATMENT Patient Details or pre-printed label Patient s NHS Number or Hospital number
Department of Clinical Haematology. Chemotherapy. Information for patients. Page 1 of 12
Department of Clinical Haematology Chemotherapy Information for patients Page 1 of 12 You may find this booklet helpful if you or someone close to you is going to have chemotherapy. It explains: what chemotherapy
Arthroscopic subacromial decompression (ASD) with or without AC joint removal
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is an ASD? Arthroscopic: Using a camera and specially designed instruments we
Lipomodelling / Fat grafting
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is lipomodelling? Lipomodelling (or fat grafting) is a procedure used to improve
MENTAL CAPACITY ACT POLICY (England & Wales)
Stalbridge Surgery Reviewed June 2017 Next review date June 2018 INTRODUCTION MENTAL CAPACITY ACT POLICY (England & Wales) The Mental Capacity Act (MCA) 2005 became fully effective on 1 st October 2007
Tacrolimus. Information for patients about using the drug Tacrolimus.
Tacrolimus Information for patients about using the drug Tacrolimus. Your consultant has recommended you start treatment with tacrolimus. This leaflet has been developed to provide you with additional
Cyclophosphamide Treatment (To be used in conjunction with the Shared Care Blood Test Monitoring Card)
Cyclophosphamide Treatment (To be used in conjunction with the Shared Care Blood Test Monitoring Card) Exceptional healthcare, personally delivered What is Cyclophosphamide Cyclophosphamide is a potent
Rituximab treatment in autoimmune blistering diseases
Rituximab treatment in autoimmune blistering diseases This leaflet explains more about having treatment with the medicine rituximab for an autoimmune blistering disease. It includes information about the
Total knee replacement
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is a total knee replacement? In a total knee replacement the cartilage surfaces
Weekly standard dose. Paclitaxel (Taxol) and carboplatin
paclitaxel (taxol) and carboplatin Paclitaxel (Taxol) and carboplatin This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may
Having inhalation sedation for your dental treatment
Having inhalation sedation for your dental treatment This aim of this information sheet is to help answer some of the questions you may have about having inhalation sedation for your dental treatment.
What happens if I cannot make decisions about my care and treatment?
Information Line: 0800 999 2434 Website: compassionindying.org.uk What happens if I cannot make decisions about my care and treatment? This factsheet explains how decisions are made about your care or
Patient agreement to investigation or treatment. Anterior Cervical Discectomy & Fusion (ACDF) Patient details (or pre-printed label)
CONSENT FORM 1(V) Patient agreement to investigation or treatment Anterior Cervical Discectomy & Fusion (ACDF) Patient details (or pre-printed label) Patient s surname/family name...... Patient s first
ECT and the law. Dr Hugh Series. Consultant old age psychiatrist, Oxford Health NHS FT Member, Law Faculty, University of Oxford
ECT and the law Dr Hugh Series Consultant old age psychiatrist, Oxford Health NHS FT Member, Law Faculty, University of Oxford Outline Assault Mental health law in E&W MHA ECT in general hospital MCA DOLS
Low dose cytarabine (Low dose Ara C) Cancer Services Information for patients
Low dose cytarabine (Low dose Ara C) Cancer Services Information for patients i Introduction This leaflet is offered as a guide to you and your family; ideally it should be read with our general information
Carboplatin & weekly paclitaxel (Taxol) (for anal cancer) Carboplatin and weekly paclitaxel (Taxol) (for anal cancer)
Carboplatin & weekly paclitaxel (Taxol) (for anal cancer) Carboplatin and weekly paclitaxel (Taxol) (for anal cancer) The possible benefits of treatment vary; for some people chemotherapy may reduce the
CENTRES 8 th International Clinical Ethics Conference Mental Health - Challenges in Clinical Ethics
CENTRES 8 th International Clinical Ethics Conference Mental Health - Challenges in Clinical Ethics Primer 1: Mental Capacity Assessments for Treatment Date: 30 th October 2018 Venue: NUSS Kent Ridge Guild
Pentostatin (Nipent )
Pentostatin (Nipent ) Pentostatin (Nipent ) This leaflet is offered as a guide to you and your family. Your treatment will be fully explained by your doctor or nurse, who will be happy to answer any questions.
Implantation of a Cardiac Resynchronisation Therapy-Defibrillator (CRT-D)
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient Implantation of a Cardiac Resynchronisation Therapy-Defibrillator (CRT-D) affix patient label What is
Methotrexate for inflammatory bowel disease: what you need to know
Methotrexate for inflammatory bowel disease: what you need to know This leaflet aims to answer your questions about taking methotrexate for inflammatory bowel disease (IBD). If you have any questions or
!This booklet is for family and friends of anyone who.!these decisions may be related to treatment they re
MENTAL CAPACITY ACT INFORMATION What is the Mental Capacity Act? The Mental Capacity Act 2005 (MCA) was implemented by parliament in 2007 and is a vitally important piece of legislation for England and
Sorafenib (Nexavar ) For thyroid carcinoma
Sorafenib (Nexavar ) for thyroid carcinoma Sorafenib (Nexavar ) For thyroid carcinoma This leaflet is offered as a guide to you and your family. Sorafenib is a type of anti-cancer treatment called a targeted
Implantation of an Implantable Cardioverter Defibrillator (ICD)
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is an Implantable? Your doctor has recommended that you have an Implantable.
Understanding Methotrexate
Understanding Methotrexate Turnberg Building Inflammatory Bowel Disease Service 0161 206 4023 All Rights Reserved 2018. Document for issue as handout. What is my medication? Methotrexate is considered
Patient agreement to investigation or treatment. Lumbar Spinal Fusion. Patient s surname/family name... Patient s first names.. Date of birth.
CONSENT FORM 1(IV) Patient agreement to investigation or treatment Lumbar Spinal Fusion Patient details (or pre-printed label) Patient s surname/family name..... Patient s first names.. Date of birth.
Bendamustine. Bendamustine. Your treatment Your doctor or nurse clinician has prescribed a course of treatment with bendamustine.
Bendamustine Bendamustine This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back,
Unit 5 MCA & DOLS. Deprivation of Liberty Safeguards (DOLS) Lasting Powers of Attorneys (LPAs) Advance Decisions to Refuse Treatment (ADRTs)
Unit 5 MCA & DOLS Unit 5 MCA & DOLS INTRODUCTION The Mental Capacity Act 2005 covering England and Wales provides a statutory framework for people who lack capacity to make decisions for themselves, or
Therapeutic mammoplasty with or without localisation
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is a (localised) therapeutic mammoplasty? A therapeutic mammoplasty is a type
4. Adults Lacking Capacity to Consent to Research
4. Adults Lacking Capacity to Consent to Research Introduction There are different laws in each UK country for research that involves adults who lack the capacity to consent to research; the correct law
Beating cervical cancer
Beating cervical cancer The HPV vaccine questions and answers for parents of girls in Year 9 and 10 This Q&A on the HPV vaccine supports the leaflet that your daughter should have been given at school.
Gemcitabine and Cisplatin (urology)
Gemcitabine and Cisplatin Gemcitabine and Cisplatin (urology) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce
Arthroscopic shoulder stabilisation
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient Including repair of the labrum, tightening of the capsule (plication) or SLAP repair affix patient label
Mental Capacity Implementation Programme. Mental Capacity Act 2005
Mental Capacity Implementation Programme Mental Capacity Act 2005 The Presentation Is an Overview and Will Cover: Part one - background and key policy Why we needed the act and who it affects The Mental
Oral cyclophosphamide in ovarian cancer
Oral cyclophosphamide in ovarian cancer Oral cyclophosphamide in ovarian cancer This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy
Package leaflet: Information for the user. Zoledronic Acid Accord 4 mg/5 ml concentrate for solution for infusion Zoledronic acid
Package leaflet: Information for the user Zoledronic Acid Accord 4 mg/5 ml concentrate for solution for infusion Zoledronic acid Read all of this leaflet carefully before you start taking this medicine
Day care and childminding: Guidance to the National Standards
raising standards improving lives Day care and childminding: Guidance to the National Standards Revisions to certain criteria October 2005 Reference no: 070116 Crown copyright 2005 Reference no: 070116
Mental capacity and mental illness
Mental capacity and mental illness The Mental Capacity Act 2005 (MCA) Mental capacity is the ability to make your own decisions. If you lose mental capacity the Mental Capacity Act 2005 (MCA) protects
what you need flu. Protect yourself and others.
swine flu vaccination: what you need to know flu. Protect yourself and others. contents What is swine flu?................ 3 About the swine flu vaccine........ 4 What else do I need to know?....... 8
Paclitaxel (Taxol) and carboplatin
Paclitaxel (Taxol) and carboplatin Paclitaxel (Taxol) and carboplatin This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may
swine flu vaccination:
swine flu vaccination: what you need to know Flu. Protect yourself and others. Contents What is swine flu?...................3 About the swine flu vaccine...........4 What else do I need to know?.........8
Mitomycin C given by injection into a vein. Cisplatin and hydration (fluids) via a drip over 6 or 18 hours.
Cisplatin & Mitomycin C Cisplatin & Mitomycin C This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the
Adjuvant bisphosphonate
Adjuvant bisphosphonate Information for patients from the Kent Oncology Centre This leaflet is intended to support you in making decisions about the role of bisphosphonates in your breast cancer care.
Vinblastine (Lymphoma)
Vinblastine (Lymphoma) Vinblastine (Lymphoma) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the
Electroconvulsive Therapy (ECT) Patient Information Leaflet
Electroconvulsive Therapy (ECT) Patient Information Leaflet Contents Page Introduction 3 What is Electroconvulsive Therapy (ECT)? 3 Why has ECT been recommended? 3 What will happen if I have ECT? 3-4 How
Patient Information Sheet
Research Trial of Treatments for Patients with Bony Metastatic Cancer of the Prostate. - TRAPEZE Patient Information Sheet Your doctor has explained to you that your prostate cancer is no longer responding